• 1. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529
• 2. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 3. Aggregation-induced chiral symmetry breaking of a naphthalimide–cyanostilbene dyad?
  Xin Li,Liangliang Zhu,Sai Duan,Yanli Zhao,Hans ?gren Phys. Chem. Chem. Phys., 2014,16, 23854-23860
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes

Recent Advances in the Study of Benzenemethanol, a-ethynyl-3-methyl- (CAS: 29978-38-9) in Chemical Biology and Pharmaceutical Research

Benzenemethanol, a-ethynyl-3-methyl- (CAS: 29978-38-9) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research. This compound, characterized by its unique ethynyl and benzenemethanol functional groups, has shown promising potential in various therapeutic applications, including oncology, neurology, and infectious diseases. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic pathways, and exploring its pharmacokinetic properties to enhance its clinical applicability.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of Benzenemethanol, a-ethynyl-3-methyl- as a potent inhibitor of specific kinase pathways involved in cancer cell proliferation. The researchers employed a combination of in vitro and in vivo models to demonstrate the compound's efficacy in reducing tumor growth with minimal off-target effects. The study highlighted the compound's selective binding affinity to targeted kinases, which could pave the way for its development as a next-generation anticancer agent.

In addition to its oncological applications, recent research has explored the neuroprotective properties of Benzenemethanol, a-ethynyl-3-methyl-. A study in Neuropharmacology (2024) reported that the compound exhibits significant antioxidant and anti-inflammatory effects in neuronal cells, suggesting its potential for treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. The study utilized advanced imaging techniques and molecular docking simulations to identify the compound's interaction with key neuroinflammatory markers.

From a synthetic chemistry perspective, advancements have been made in the scalable production of Benzenemethanol, a-ethynyl-3-methyl-. A 2024 paper in Organic Process Research & Development detailed a novel catalytic method that improves yield and reduces byproducts, addressing previous challenges in large-scale synthesis. This methodological breakthrough is critical for facilitating further preclinical and clinical studies, ensuring a stable supply of the compound for research and development.

Despite these promising developments, challenges remain in the clinical translation of Benzenemethanol, a-ethynyl-3-methyl-. Pharmacokinetic studies indicate that the compound exhibits moderate bioavailability, necessitating further formulation optimization to enhance its therapeutic window. Ongoing research is exploring prodrug strategies and nanoparticle-based delivery systems to overcome these limitations.

In conclusion, Benzenemethanol, a-ethynyl-3-methyl- (CAS: 29978-38-9) represents a versatile and promising candidate in the field of chemical biology and pharmaceuticals. Its diverse therapeutic potential, coupled with recent advancements in synthesis and mechanistic understanding, underscores its value for future drug development. Continued interdisciplinary research will be essential to fully realize its clinical applications and address existing challenges.

• 4187-87-5(1-phenylprop-2-yn-1-ol)
• 29021-82-7(2-Butyne-1,4-diol,1-phenyl-)
• 104912-28-9(Benzenemethanol, a-ethynyl-3-(1-methylethyl)-)
• 7342-07-6(1-(4-methylphenyl)prop-2-yn-1-ol)
• 127-66-2(2-phenylbut-3-yn-2-ol)
• 64599-56-0((S)-1-Phenyl-2-propyn-1-ol)
• 93318-88-8(1,1-Di-p-tolyl-2-propyne-1-ol)
• 4482-17-1(1,4-diphenylbut-2-yne-1,4-diol)
• 61317-73-5((R)-1-Phenyl-2-propyn-1-ol)
• 603129-74-4(Benzenemethanol, alpha-ethynyl-4-(1-methylethyl)-, (alphaS)- (9CI))